{
  "abstract": "This case describes a woman in her mid-40s with recurrent colorectal cancer who developed severe dermatologic toxicity during panitumumab-based therapy. Three months after treatment initiation, she developed a diffuse acneiform eruption, pronounced xerosis and painful periungual inflammation with exuberant granulation tissue consistent with epidermal growth factor receptor (EGFR)-inhibitor–induced paronychia. Multidisciplinary, guideline-concordant supportive care (including prompt topical measures and short-course systemic therapy) achieved symptom control and allowed continuation of anticancer treatment. This report underscores the importance of early recognition and structured management of EGFR-inhibitor toxicities to prevent treatment disruption and preserve quality of life.",
  "authors": [
    {
      "affiliations": [
        "Ortopedia and travmatology, Elazığ Fethi Sekin City Hospital, Elâzığ, Turkey"
      ],
      "name": "Omer Esmez"
    },
    {
      "affiliations": [
        "Firat Universitesi, Elazığ, Turkey"
      ],
      "name": "Merve Yıldız Esmez"
    },
    {
      "affiliations": [
        "Erzurum Technical University, Erzurum, Turkey"
      ],
      "name": "Gulnİhal Deniz"
    }
  ],
  "title": "Relationship between recurrent colorectal cancer and EGFR inhibitor-induced dermatological side effects: a focus on paronychia",
  "uid": "9e378d4e-e164-5b9c-bb73-db0331d5ce82"
}